Abstract-This perspective on blood-materials interactions is intended to introduce the set of papers stemming from the symposium, "Devices and Diagnostics in Contact with Blood: Issues in Blood Compatibility at the Close of the 20th Century," organized on August 4-6, 1999 at the University of Washington by the University of Washington Engineered Biomaterials (UWEB) Engineering Research Center. This article outlines some of the history of blood contacting materials, overviews the work that has originated at the University of Washington over the past 28 years, speculates on the origins of the controversies on blood compatibility and considers the issues that should be addressed in future studies.
A vast number of research articles and reviews have been written on the subject of blood compatibilit y. The widespread clinical application of devices that contact blood provide both humanitarian and nancial sides to any discussion of this topic. Finally, there is considerable intellectual richness and excitement in this area of exploration.
Three subjects dominate the blood-materials interaction literature.
(1) How can we measure blood compatibility ? (2) What biomaterials are blood compatible? (3) What is the biological basis of the reaction of materials with blood. In spite of the extensive body of literature developed over some 35 years, there is little consensus on points (1) and (2) and just faint glimmers of progress on point (3) . For these reasons, the symposium , Devices and Diagnostics in Contact with Blood: Issues in Blood Compatibilit y at the Close of the 20th Century, was organized on August [4] [5] [6] 1999 at the University of Washington by the University of Washington Engineered Biomaterials (UWEB) Engineering Research Center. The written record of the lectures presented will help readers focus on key themes surrounding the subject of blood compatibility and highlight progress.
I, personally, have expressed strong opinions about blood compatibility and blood interactions with materials [1] . Hence, I'd like to review some history, discuss a few key research papers that shaped my perspective on this subject, and offer recent thoughts relevant to the research now ongoing in this eld.
A fascination with the possibility of using synthetic materials in contact with blood extends back to antiquity. Although the earliest records are hard to come by, Fig. 1 shows a diagram of a heart pump device from a book published in 1881. More recently, an article appeared in the newspaper describing a 3-week old baby with a pacemaker. Thus, in some hundred plus years, cardiovascular devices have moved from a visionary dream to an almost routine, lifesaving reality. The substantial numbers of cardiovascular devices used in humans listed in Table 1 points to their success at saving lives and improving the quality of life.
Although cardiovascular devices are widely used in humans, there are serious clinical complications. In 1988 I made a slide entitled "Blood Compatibility : Clinical Manifestations" that outlined problems with many cardiovascular devices. Remarkably, I can show this same slide in 1999 with no changes. I was concerned in 1988 that:
² small diameter vascular grafts fail early due to thrombolic occlusion, ² embolic complications are noticed with arti cial hearts, ² embolic problems frequently occurred with catheters, ² non-tissue heart valves require lifelong anticoagulation , ² blood contacting biosensors fail due to thrombus accumulation, ² long-term implants are seen to be continuously platelet reactive, ² signi cant blood damaged is observed during hemodialysis and extracorporeal blood oxygenation, ² venous prostheses cannot be made at all.
These issues still plague blood contacting devices. In addition, for 1999, I could add to this list the blood interaction problems associated with endoluminal stents. Since we have the rst meeting in many years on the subject of blood compatibility, let me elaborate on the historical perspective. In 1858, the father of pathology, Rudolf Virchow, proposed that three factors in uenced blood coagulation: ow, the blood and the nature of the surface contacting the blood. These perceptive observations from 1858 are still relevant today and are often referred to as Virchow's Triangle (Fig. 2 ).
There were other interesting observations and proposals that form the historical background to our present day eld: ² It has been known for at least 100 years that wax treated glass inhibited blood coagulation compared to clean glass.
² Alexis Carrel developed surgical methods for joining blood vessels, for which he was given the Nobel Prize in Medicine (1912).
² Charles Lindbergh and Alexis Carrel published descriptions of interesting devices that are precursors to modern blood pumps [2] . ² Modern blood contacting biomaterials may have started after World War II with the vascular prosthesis developed by Voorhees from parachute cloth [3] . ² In the 1950s and 1960s, surgeons such as C. William Hall, Adam Weslow and Lester Sauvage assumed leadership roles in demonstrating that remarkable vascular replacements could be performed with devices made from rather ordinary materials. ² By the late 1960s and early 1970s, the early theorists in this eld started thinking about the nature of blood reactions with solid surfaces. Individuals like Robert Baier, Phil Sawyer, and Leo Vroman offered intriguing hypotheses that are discussed to this day. ² A landmark in the history of blood compatible materials occurred when groups working with Vincent Gott and Robert Leininger rst thought to heparinize materials [4, 5] . This led Allan Hoffman and Gottfried Schmer at the University of Washington to publish a seminal paper in which heparin was covalently immobilized to surfaces [6] . ² In 1979, at an American Institute of Chemical Engineers meeting in Boston, Edward W. Merrill proposed the concept of using poly(ethylene glycol) on surfaces to inhibit blood interactions. From its beginnings in 1970, blood compatibility research has been an important theme in the University of Washington's biomaterial program. Blood compatibility research efforts at the University of Washington have addressed:
² heparinization [6] , ² hydrogel surface modi cation [7 -9] , ² polyurethanes in contact with blood [10 -12] , ² RF-plasma treatment of materials and their blood interactions [13, 14] , ² the assessment of blood compatibility [10, 15] , ² vascular grafts [13] , ² platelet reactions with surfaces [11, 12, 16 -18] , ² anticoagulant release devices [19] . Over some 30 years, the University of Washington has contributed broadly to blood compatibility. The research in this area started with a grant to Allan Hoffman from the now-defunct Atomic Energy Commission (AEC) to work on blood contacting surfaces for a plutonium powered arti cial heart [20, 21] . At that time we were intrigued with another development associated with radioactivity, using 60 Co gamma radiation to graft hydrogels to surfaces. The hypothesis driving the research at that time focused on developing a water interface for enhanced blood compatibilit y. Water, of course was 'blood compatible'. Therefore, the higher the water content within a hydrogel grafted to a surface, the more 'water-like' the surface contacting the blood would be.
A series of well characterized radiation grafted hydrogels was developed [8, 22, 23] . In the early 1970s, the National Institutes of Health (NIH) Heart and Blood Institute contracted with various research groups to set up tests to assess the blood compatibilit y of potential surfaces for arti cial heart applications.
One of those evaluation systems was developed by Dr. Vincent Gott, and was widely known as the Gott ring or vena cava ring test [24] . Rings roughly 5 mm in diameter and 5 mm in length were surgically placed in the vena cava of dogs. At 2 h or 2 weeks they were explanted and examined for thrombus. Dr. James Whif n from the University of Wisconsin collaborated with us on performing vena cava ring tests. The results of some of the tests are illustrated in Fig. 3 . Silastic (silicone rubber) rings were the control. These were compared to Silastic rings radiation grafted with various levels of hydrophilic 2-hydroxyethy l methacrylate monomer. The gure shows the surgeon's observation of the clot that accumulated in the rings. It is obvious that the Silastic accumulated much more thrombus than any of the hydrogel grafts. We thought we had solved the problem of blood compatibility. However, another of the NIH blood compatibility assays, that developed by Dr. Burt Kusserow of the University of Vermont, gave us a very different picture of the blood compatibilit y of these grafted rings.
Dr. Kusserow's assay used similar rings, but these were inserted in the renal arteries of dogs [25] . The lumen of the rings could be examined for thrombus build-up. In addition, the kidneys of the animals immediately downstream from the rings could examined for infarcts (areas of necrotic damage where thrombi washed downstream from the rings were trapped in the ltration system of the kidney occluding small blood vessels). Our grafted hydrogels were again found to have little thrombus buildup within the rings. However, the kidneys downstream from these rings showed extensive infarct damage. The conclusion from these two tests was that although the hydrogel surfaces were non-thromboadherent , they were thrombotic. The clots formed were detached in the blood ow where they could induce damage downstream.
Both the vena cava ring test and the renal embolus ring test had a number of downsides. The tests were dependent on signi cant involvement of a skilled surgeon. They were non-quantitative . A dog had to be sacri ced for every specimen examined. For these reasons, we felt it was essential to develop a quantitative model in our own labs that would permit us to examine many more specimens.
We were fortunate to have Professor Laurence Harker in our School of Medicine during the 1970s. Dr. Harker had developed a baboon arterial-venous (A-V) shunt model to measure platelet damage. Allan Hoffman took on a new chemical engineering graduate student at that time, Stephen Hanson. His thesis research was part of a collaboration with Dr. Harker to evolve a quantitative assay based on the baboon A-V system. Steve Hanson worked out a mathematical model of the blood-surface reaction occurring in the baboon shunt system [26] . His equation normalizes or takes into account factors that were often uncontrolled in other blood interaction models. The model provided a useful number to describe the reaction of shunt materials with blood. The k-value calculated from platelet survival time, the animal platelet count and the shunt geometry, is a rst order rate constant of reaction of platelets to surfaces with units of platelets destroyed per square centimeter of shunt surface per day.
The A-V Shunt model had many advantages:
² quantitative data was produced, ² the shunt was the analogous con guration to clinically used devices, ² the baboon is hematologicall y similar to humans, ² the model was validated with clinical studies from Dr. Harker's research program, ² many tests were possible on one animal, ² long term monitoring (weeks) was possible, ² the results were independent of the diameter of the shunt, the shunt length, ow rate, platelet count, surgical variables, and heparinization. We used the AV shunt model to study tubes grafted luminally with various hydrogels and we got surprising results [7, 8, 10] . We found that as the hydrogel water content increased, the platelet reactivity of the surfaces also increased (higher k-values). This is opposite to what we had predicted, i.e. that higher water content surfaces would look more like water, and what could be more non-platelet-reactiv e than water?
It was also interesting that material chemistry seemed to make little difference. We studied methacrylic esters, acids, amides and hydroxy polymers. The only parameter of importance was the hydrogel graft equilibrium water content.
We also asked what happened to those platelets that were removed from circulation? To investigate this, we collaborated with Professor Larry Reynolds. He developed a laser light scattering system that allowed us to look in real time at the size and number distribution s of particles in whole blood [27, 28] . We found that high water content hydrogels generated showers of emboli downstream from the shunt. The mass of emboli roughly correlated with the water content of the gel. Thus, although blood elements did not adhere to the hydrogels, these hydrated surfaces caused platelet activation leading to aggregation down stream. These observations with the baboon A-V shunt system and the laser light scattering system were consistent with the results from the vena cava ring test and the renal embolus test. High water hydrogels were non-thromboadhesiv e but platelet consumptive and embolic. Our results, published in the early 1980s, were controversial. It wasn't until the publication of papers from the Sefton group in Toronto in the late 1980s and early 1990s that corroboration of these general observations on hydrogel blood compatibility was seen, this time using a platelet consumption model in a dog [29, 30] .
In the early 1980s we received funding from the Arti cial Heart Program of the NIH Heart and Blood Institute to explore the blood compatibility of polyurethanes, speci cally, the relationship between surface properties and blood reactivity. By correlating parameters calculated from electron spectroscopy for chemical analysis (ESCA) data with platelet consumption numbers, we showed that the higher the polar contributio n to the surface properties, the higher the platelet consumption [10] (Fig. 4) . Thus, hydrophobic polyurethane surfaces were less platelet damaging. Unfortunately, the polyurethane chosen for the rst arti cial hearts to be implanted in humans was, based on its ESCA signal, highly platelet damaging. This experimental observation seemed to have strong parallels to substantial clinical problems noted with the rst arti cial hearts [31] .
In the early 1980s extensive work occurred at the University of Washington on a new vascular prosthesis based upon a uoropolymer RF-plasma surface modi cation [13, 32, 33] . This project, part of the Ph.D. thesis of Andrew Gar nkle (now an M.D.) used both the baboon A-V shunt model and laser emboli detection. We concluded that this plasma uoropolymer treatment was less thrombotic and less emboli than the untreated Dacron or Te on controls. Since more hydrophobic polyurethanes were also found to have lower platelet reactivities, it was consistent that these highly hydrophobi c uoro-modi ed surfaces were relatively non-reactive.
In 1982, I was invited to participate in an NIH consensus development conference on biomaterials and to address the issue of blood compatibilit y. I compiled a list of the many different blood compatibilit y evaluation systems that were in use at that time [34] . These evaluation systems were developed by solid research groups, and each of these had considerable effort behind them associated with appropriate controls and data reproducibilit y. The literature compilation was presented in a table in the article based on my talk [34] . Each of the rows in the table listed a different biomaterial, for example, polyethylene . Each column was labeled with a different blood compatibilit y evaluation method (e.g., the baboon A-V shunt system). Based on criteria established for each of the methods, the blood compatibilit y of materials listed in each row was rated poorly blood compatible, moderately blood compatible, or highly blood compatible. Going across essentially every row, one nds poor, medium, and high ratings. Thus, depending upon which group did the analysis, the same material could be bad, moderate or good for use in a blood contact application.
If an engineer wanted to choose a material for a given application using the data in the literature, which research group should that engineer believe? The groups included in this study were all quality research groups. My conclusion was that from the literature we could not draw conclusions as to which materials are blood compatible. It was interesting to speculate on the factors that might account for differences in ranking from one research group to another: ² animal species -dogs, goats, rats, baboons and humans were used, ² interaction times between blood and materials ranging from seconds to days, ² the blood shear regime ranging from static to high shear ow, ² the wide range of test surface con gurations studied including shunts, beads, rotating probes and other shapes, ² parameters being measured to assess blood compatibility including platelet adhesion, thrombus formation, platelet consumption , bleeding time, etc.
Considering the many variables, rationales and approaches offered in the papers included in this consensus conference analysis, it seemed unlikely that a consensus could ever be reached.
About this time we had a setback at the University of Washington. The animal rights movement basically closed down our baboon shunt model. This brought our blood compatibilit y evaluation program to a standstill.
In an attempt to develop a blood compatibilit y evaluation method that might generate data consistent with that obtained from the baboon shunt model, a PhD candidate, Claire Haycox (now an M.D.) developed a new model [15] . Her thesis project used freshly collected human blood. The project attempted to address:
² venipuncture and minimizing blood activation during collection, ² minimizing blood activation during further blood manipulation steps, ² temperature variation affecting blood reactivity, ² heparinization variables, ² blood contact with surfaces in the system other than the test surface.
Claire Haycox developed a closed loop system powered by a peristaltic pump to achieve ows (wall shear rates) consistent with those used in the baboon A-V shunt model. Since greater than 60 min of pumping led to extensive hemolysis damage to the blood, pumping times were kept to 60 min or less. A number of factors were measured as a function of time including blood platelet count, adherent platelet count and¯-thromboglobuli n release from platelets. Additional detail is provided in Fig. 5 and in ref. [15] . Although this closed loop model suffered from signal to noise problems, experimental variability and the need for meticulous experimental technique, four reactions of materials with blood were noted (Fig. 6 ):
² Biomer polyurethane continually reacted with the blood, accumulated thrombus and shed emboli, ² poly(vinyl alcohol) continually reacted with the blood but did not adhere blood elements, Figure 5 . The experimental plan for the circulating loop platelet interaction test system described in ref. [15] .
² polyethylen e initially reacted with the blood and adhered platelets, but, in time, formed a passivation layer consisting of thinly spread platelets that was no longer reactive, ² a hydrophobi c octadecyl-derivatize d polyurethane was found to be almost non-reactive with the blood.
These results were remarkably consistent with earlier baboon studies. Biomer was always noted to be highly platelet consumptive in earlier tests. Hydrogels were always found to be platelet consumptive and non-thromboadherent . Polyethylene always showed low platelet reactivity with blood. The octadecyl polyurethane was not tested in earlier studies. However, all earlier studies demonstrated that hydrophobi c surfaces such as this one were non-platelet reactive.
In recent years, a number of groups have made important advances in blood compatibilit y assessment. Yet we still have no widely recognized test systems, nor do we have an agreed upon list of blood compatible materials. This symposium , and the papers that follow in this issue, focus on the latest advances in blood compatibilit y testing and blood compatible materials.
Here are a few of my thoughts to help focus discussions on blood compatibilit y as we go into the 21st century:
² White cells are always noted at material surfaces in the early phases of reaction with blood. Macrophages are seen in the interstices of vascular prostheses even after years of implantation. Perhaps we are seeing subtle Figure 6 . Four interactions of material with blood platelets observed in the experiments described in ref. [15] . (A) Platelets adhere, activate and embolize; noted for Biomer; (B) Platelets adhere, and spread to a smooth layer thus passivating the surface against further platelet reaction: noted for polyethylene; (C) Platelets interact with the activating surface, but they do not adhere: noted for poly(vinyl alcohol); (D) platelets neither adhere nor activate: noted for a polyurethane synthesized in our laboratories with octadecyl side chains.
manifestations of the foreign body reaction leading to poor healing of vascular prosthesis? Possibly blood compatibilit y itself may be directly related to in ammation and the foreign body reaction?
² Why do we not yet have rules for developing blood compatible materials? ² What is blood compatibility ?
² What materials are blood compatible?
² How do we test for blood compatibility ?
² What is the signi cance of blood microparticles noted in more recent studies [15, 35] ?
² What are the relationship s between healing and thrombosis?
² Do calci cation processes offer insights useful for blood compatibility? ² What are important issues for blood compatibilit y, c. 2000?
